Other than GBM, CNS-WHO grade 4 astrocytoma carry a mutation of isocitrate dehydrogenase 1 (IDH1) [1], which has been linked with increased sensitivity to treatment with BH3-mimetics targeting BCL-xL [27]. The gene discussed is BCL2L1; the disease is glioblastoma.